Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program globenewswire.com/NewsRoom/R…
1
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update https://nitter.cf/t.co/FTHUrvR2MU
Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7 https://nitter.cf/t.co/JtVKu57Wgo
PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS https://nitter.cf/t.co/0ctq4zrKpF
Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU) https://nitter.cf/t.co/ixWvGcJCJB
Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review https://nitter.cf/t.co/ZWEOpdrl4H
Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting https://nitter.cf/t.co/OWZ1w4Pf2e
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint https://nitter.cf/t.co/ivLfak0wWV
Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd https://nitter.cf/t.co/6ULFwZVke9
2
Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting https://nitter.cf/t.co/7cbSovmBhZ
Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer https://nitter.cf/t.co/fydPYY7TsV
Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results https://nitter.cf/t.co/PIsn9uWEar
Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations https://nitter.cf/t.co/NANWu2nnJR
Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update https://nitter.cf/t.co/ijRqSOWFk5
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) https://nitter.cf/t.co/qukEr8Pyx6
Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer https://nitter.cf/t.co/bZCuJOy7Ue
1
Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 https://nitter.cf/t.co/qI3RnxN6uU
1
Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis https://nitter.cf/t.co/JEzscvETCa
